GILDER GAGNON HOWE & CO LLC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.

Quarter-by-quarter ownership
GILDER GAGNON HOWE & CO LLC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$25,709,095
-44.9%
1,246,199
-21.1%
0.39%
-38.7%
Q2 2023$46,624,191
+22.2%
1,579,945
-4.6%
0.64%
+0.9%
Q1 2023$38,163,384
-22.3%
1,656,397
-6.3%
0.63%
-31.1%
Q4 2022$49,144,216
-14.1%
1,767,142
-5.2%
0.92%
-8.1%
Q3 2022$57,184,000
-0.7%
1,863,277
-4.8%
1.00%
-2.8%
Q2 2022$57,589,000
-31.7%
1,956,820
-25.3%
1.03%
+31.8%
Q1 2022$84,260,000
-34.9%
2,619,217
-9.7%
0.78%
+5.8%
Q4 2021$129,345,000
-8.5%
2,900,114
+3.5%
0.74%
+0.4%
Q3 2021$141,411,000
-36.4%
2,802,994
-1.2%
0.73%
-32.9%
Q2 2021$222,435,000
+29.7%
2,835,733
-5.6%
1.09%
+18.1%
Q1 2021$171,560,000
-36.4%
3,004,553
-6.7%
0.92%
-30.9%
Q4 2020$269,694,000
+127.0%
3,219,843
-2.9%
1.34%
+82.9%
Q3 2020$118,817,000
+45.2%
3,316,130
-2.0%
0.73%
+14.4%
Q2 2020$81,855,000
+43.4%
3,385,233
+3.8%
0.64%
-6.6%
Q1 2020$57,100,000
+407757.1%
3,261,022
+547051.3%
0.68%
Q1 2019$14,000
-12.5%
596
-24.3%
0.00%
Q4 2018$16,000
-94.2%
787
-93.9%
0.00%
-100.0%
Q3 2018$278,000
+33.7%
12,808
-5.9%
0.00%
+50.0%
Q2 2018$208,000
-22.7%
13,616
-0.5%
0.00%
-33.3%
Q1 2018$269,000
+13.5%
13,683
-9.6%
0.00%0.0%
Q4 2017$237,00015,1300.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Crestline Management, LP 7,705,039$343,645,00025.68%
Casdin Capital, LLC 1,500,000$66,900,0001.89%
Flagship Pioneering Inc. 2,619,968$116,851,0001.81%
SECTORAL ASSET MANAGEMENT INC 189,600$8,456,0001.27%
Integral Health Asset Management, LLC 100,000$4,460,0001.23%
Temasek Holdings (Private) Ltd 5,369,487$239,479,0000.86%
Goldstream Capital Management Ltd 78,418$3,497,0000.86%
Yiheng Capital Management, L.P. 335,184$14,949,0000.76%
GILDER GAGNON HOWE & CO LLC 2,900,114$129,345,0000.74%
Artal Group S.A. 600,000$26,760,0000.73%
View complete list of DENALI THERAPEUTICS INC shareholders